ArticleRheumatology international2004
Antiannexin V autoantibody in thrombophilic Behçet's disease.
Article in Rheumatology international, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 13 citations in OpenAlex.
- Redistribution of peripheral blood immune cell subsets and remodeling of intercellular communication in rare Behçet's disease: a single-cell transcriptomics study.Frontiers in medicine · 2026Article
- Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus.Rheumatology international · 2012Article
- Behçet's Disease as a Model of Venous Thrombosis.The open cardiovascular medicine journal · 2010Article
- Immunoproteomic identification of bovine pericardium xenoantigens.Biomaterials · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We propose that thrombosis in Behçet's syndrome may be due to disruption of the annexin V shield by antiphospholipid antibodies. Measurement of antiannexin V antibodies may be of value in confirming diagnosis and evaluating the risk of venous and arterial thrombosis in patients with Behçet's syndrome. To evaluate the efficiency of antiannexin V antibody in the formation of thrombosis, 53 male patients with Behçet's disease according to international study group criteria were involved in this study. The age range was 20-28 years (mean 23+/-3.4). All of these patients had been taking colchicum. Those taking medications that interfere with antiannexin V autoantibody levels were excluded, and serum samples were taken during the active period. Group I included 26 Behçet's patients with well-documented thrombosis, group II included 27 Behçet's patients without thrombosis, and group III was comprised of 27 healthy controls. There were no statistical differences between the mean concentrations of IgG and IgM antiannexin V autoantibodies in the three groups. The results indicate that these antibodies may not be associated with the pathogenesis of thrombotic events in patients with Behçet's syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.